A recent publication, “Three Methods to Produce Rare Cannabinoids: Cultivation, Chemical Synthesis, and Biosynthesis,” of BiofuelDigest successfully differentiated between cultivation, chemical synthesis, and biosynthesis. The writer of the article and Founder of BioMedican, Max Mikheev, highlighted BioMedican’s approach to biosynthesize rare cannabinoids from proprietary yeast Yarrowia Lipolytica (YL).
The cannabis plant contains many rare cannabinoids apart from some major cannabinoids. The majority of these cannabinoids will lead the cannabis industry due to their potential health and medical benefits. Several production methods such as cultivation, chemical synthesis, and biosynthesis made these cannabinoids more affordable and accessible.
Human has always been cultivating cannabis plant to get its known active constituents. The output of farmers’ efforts after growing and harvesting cannabis plants was a mixture of cannabinoids containing a small quantity of rare cannabinoids. For example, 10 kilograms of cannabis plants can produce less than 2 grams of rare cannabinoids. This small quantity is not enough to meet a large industry’s requirements. Moreover, this tedious grow-harvest method’s resulting product is impure, costly, and inconsistent. The stringent regulatory requirements such as taxation also contribute to the overall cost of rare cannabinoids.
Chemical synthesis is a leading method of rare cannabinoids synthesis nowadays. In chemical synthesis, a chemical reaction in laboratories yields rare cannabinoids that are non-natural occurring forms of cannabinoids. Sometimes, these rare cannabinoids can be toxic and potentially pose serious life threats. Though chemical synthesis is an efficient and cheap method, its artificially produced products accompany various side effects that need serious consideration of investors who want to invest in the cannabis market.
Biosynthesis is a well-known and best method of rare cannabinoid production. Biosynthesis is a way to yield desired cannabinoids and carotenes by natural means of an organism’s biological processes. According to Max Mikheev, biosynthesis “overcomes the large gap in the supply chain, reduces the environmental footprint, decreases the time of production, circumvents regulatory oversight, and produces high-quality cannabinoids with the exact chemical structures as naturally occurring cannabinoids.” Several genetically engineered enzymes, NphB and THCA synthase, optimize proprietary yeast Yarrowia Lipolytica (YL), producing CBGA and other rare cannabinoids. However, non-proprietary yeast produces undesirable byproducts.
BioMedican has efficiently developed a biosynthesis method with proprietary yeast Yarrowia Lipolytica (YL) that produces cheap but highly-quality rare cannabinoids more efficiently. We invite investors to smartly invest in the biosynthesis method designed by the best researchers team at BioMedican to lead the cannabis market in the future.